同步寡转移性前列腺癌所有可见肿瘤的直接治疗:全肿瘤根除或全蒙蒂治疗
综述探讨同步寡转移性前列腺癌中联合局部治疗、系统性治疗与转移灶定向治疗(MDT)的「全肿瘤根除」(TET)或「全蒙蒂治疗」(FMT)策略。回顾性研究显示细胞减灭性根治性前列腺切除或放疗联合MDT及联合系统治疗结果良好,部分病例PSA不可测且睾酮非去势;一项对比试验(±MDT)显示总生存获益证据。前瞻性试验表明该强化策略可行有效,但所有研究依赖传统影像且缺乏长期前瞻性数据。
要点
- TET/FMT联合局部治疗、MDT与联合系统治疗在同步寡转移前列腺癌中显示 promising 结果
- 部分病例可达PSA不可测与非去势睾酮,一项对比试验(±MDT)显示总生存获益证据
- 现有研究均依赖传统影像且缺乏长期前瞻性数据,需等待正在进行的临床试验
核心结论
- 联合局部治疗、MDT与联合系统治疗的TET/FMT策略在同步寡转移性前列腺癌中显示有前景的肿瘤控制结果。
- 前瞻性试验表明该强化治疗策略可行且有效,相当比例病例达到生化缓解和无病状态。
研究设计与样本
- 本文为综述,汇总回顾性研究、一项对比试验(±MDT)及前瞻性试验的结果。
主要发现
- 回顾性研究显示细胞减灭性根治性前列腺切除或放疗联合MDT及联合系统治疗结果有前景。
- 多项研究显示相当比例病例达到PSA不可测且睾酮非去势。
- 一项对比试验(±MDT)显示总生存获益的一些证据。
- 前瞻性试验显示相当比例病例达到生化缓解和无病状态。
临床怎么用
- 对新诊断且仅有少数转移灶的前列腺癌患者,局部治疗、激素药物及针对所有转移部位的治疗后肿瘤控制结果有前景。
局限性
- 所有研究均依赖传统影像。
- 缺乏长期前瞻性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent advances in the management of synchronous oligometastatic prostate cancer (PC) highlight the potential of combining local and systemic therapies. However, there is growing interest in metastasis-directed therapy (MDT) in this setting. When all modalities are combined, this is referred as "total eradication of tumour" (TET) or "full monty treatment" (FMT). Retrospective studies have revealed promising outcomes with approaches such as cytoreductive radical prostatectomy or radiotherapy alongside MDT and combination systemic therapy. Multiple studies have demonstrated a significant proportion of cases with undetectable prostate-specific antigen and noncastrate testosterone, while one comparative trial (± MDT) revealed some evidence of an overall survival benefit. Results from the prospective trials indicate the feasibility and effectiveness of this intensive treatment strategy, with biochemical remission and disease-free states achieved in a significant proportion of cases. Overall, limitations persist, including a reliance on conventional imaging in all studies and the absence of long-term prospective data. Ongoing trials will provide definitive insights into the treatment efficacy and safety of TET/FMT. PATIENT SUMMARY: For patients with a new diagnosis of prostate cancer with only few metastases, cancer control results after treatment with local therapy, hormonal agents, and treatment targeted to all metastatic sites are promising. Further clinical trials of this approach with the inclusion of new scan techniques are eagerly awaited.
引用
- Giesen A, De Preter N, Fazekas T, et al. Direct Treatment of All Visible Tumour in Synchronous Oligometastatic Prostate Cancer: Total Eradication of Tumour or the Full Monty Treatment. Eur Urol Oncol. 2025. PMID: 40300920. doi:10.1016/j.euo.2025.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。